Chinanews.com, November 21st, title: Four departments announced the third batch of anti-cancer drugs and rare disease drugs that are subject to value-added tax policies

  China-Singapore Finance and Economics reporter Zhao Jianhua

  In order to encourage the development of the pharmaceutical industry and reduce drug costs for patients, the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Drug Administration announced on the 21st the list of the third batch of anti-cancer drugs and rare disease drugs that are subject to the VAT policy.

  From December 1, 2022, the anti-cancer drugs and rare disease drugs included in the list will implement relevant value-added tax policies in accordance with the previously announced policies.

The third batch of lists involves more than 70 types of preparations and raw materials.

  The Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Drug Administration announced in April 2018 that starting from May 1, 2018, general value-added tax payers who produce, sell, wholesale, and retail anti-cancer drugs can choose to follow the simple The method calculates and pays value-added tax according to the 3% levy rate; for imported anti-cancer drugs, the import link value-added tax is levied at a reduced rate of 3%.

  In February 2019, the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Drug Administration announced that from March 1, 2019, general value-added tax payers who produce, sell, wholesale, and retail rare disease drugs can choose to follow the The simple method calculates and pays value-added tax according to the 3% levy rate; for imported rare disease drugs, the import link value-added tax is levied at a reduced rate of 3%.

  The Ministry of Finance and other four departments emphasized that the anti-cancer drugs and rare disease drug preparations in each batch list must have been approved for marketing, and the corresponding dosage forms are subject to the actual dosage forms approved by the national drug supervision and management department.

(Finish)